American Society of Clinical Oncology

SHERPA: White

People

  1. Motzer
    Motzer
  2. Bajorin
    Bajorin
  3. Bochner
    Bochner
  4. Herr
    Herr
  5. Hakimi
    Hakimi
  6. Sheinfeld
    Sheinfeld
  7. Russo
    Russo
  8. Al-Ahmadie
    Al-Ahmadie
  9. Coleman
    Coleman
  10. Iyer
    Iyer

Groups

  1. Surgery (402)
  2. Urology (402)
  3. Department of Medicine (246)
  4. Solid Tumor Oncology Division (244)
  5. Genitourinary Oncology Service (242)
  6. Survivorship Research (153)
  7. Epidemiology and Biostatistics (142)
  8. Human Oncology and Pathogenesis Program (110)
  9. Department of Pathology and Laboratory Medicine (101)
  10. GSK Faculty (90)
Search Within
  1. "Urology"
Formats
  1. Meeting Abstract (272)
  2. Journal Article (128)
  3. Correspondence (1)
  4. Guidelines (1)
Groups
  1. Surgery (402)
  2. Urology (402)
  3. Department of Medicine (246)
  4. Solid Tumor Oncology Division (244)
  5. Genitourinary Oncology Service (242)
  6. Survivorship Research (153)

More Groups

People
  1. Dean Bajorin (119)
  2. Robert Motzer (105)
  3. Bernard Bochner (75)
  4. Peter Scardino (64)
  5. George Bosl (63)
  6. Harry Herr (63)

More People

Years
  1. 2025 (6)
  2. 2024 (15)
  3. 2023 (15)
  4. 2022 (17)
  5. 2021 (17)
  6. 2020 (22)

More Years

Publications
  1. Journal of Clinical Oncology (392)
  2. JCO Precision Oncology (5)
  3. Journal of Oncology Practice (3)
  4. JCO Clinical Cancer Informatics (2)

Results (402)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Radical prostatectomy (RP) versus radiotherapy (RT) in high-risk prostate cancer (HR-PCa): Emulated randomized comparison with individual patient data (IPD) from two phase III randomized trials (RCTs)
    Meeting Abstract

    Roy, S.; Sun, Y. L.; Eastham, J. A.; Gleave, M.; Beltran, H.; Kishan, A. U.; Jia, A. Y.; Zaorsky, N. G.; Garcia, J. A.; Small, E. J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Association between clonal hematopoiesis and survival after nephrectomy in patients with renal cell carcinoma
    Meeting Abstract

    Khandwala, Y.; Ruthen, N.; Kotecha, R. R.; Russo, P.; Coleman, J.; Reznik, E.; Hakimi, A. A.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • The Oncopig bladder cancer model, an innovative large animal platform for evaluating treatment effects
    Meeting Abstract

    Jayalath, V.; Autlitzky, A.; Kudinova, N.; Coleman, J.; Schook, L. B.; Schachtschneider, K.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Updated long-term follow-up from a phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy for patients with high-grade upper tract urothelial carcinoma
    Meeting Abstract

    Jayalath, V.; Teo, M. Y.; Assel, M.; Rodriguez, D.; Meyerson, A.; Bochner, B. H.; Dalbagni, G.; Donat, S. M.; Herr, H. W.; Cha, E. K.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • The impact of micropapillary histology and clinical staging on overall survival in bladder cancer: A retrospective analysis
    Meeting Abstract

    Alkazemi, M. H.; Alam, S. M.; Zhang, A.; Pietzak, E. J.; Donat, S. M.; Herr, H. W.; Bochner, B. H.; Chen, J. F.; Al-Ahmadie, H.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Adjuvant nivolumab for localized renal cell carcinoma at high risk of recurrence after nephrectomy: Part b of the randomized, placebo-controlled, phase III CheckMate 914 Trial
    Journal Article

    Motzer, R. J.; Bex, A.; Russo, P.; Tomita, Y.; Cutuli, H. J.; Rojas, C.; Gross-Goupil, M.; Schinzari, G.; Melichar, B.; Barthélémy, P.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: Results from Part B of the randomized, phase 3 CheckMate 914 trial
    Meeting Abstract

    Motzer, R. J.; Bex, A.; Russo, P.; Tomita, Y.; Cutuli, H.; Rojas, C.; Gross-Goupil, M.; Schinzari, G.; Melichar, B.; Barthelemy, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • HER2 and PD-L1 immunohistochemistry (IHC) expression, and HER2 genomic alterations: Associations and clinical outcomes for advanced bladder cancer
    Meeting Abstract

    Aggen, D. H.; Shah, N. J.; Zheng, J.; Alam, S. M.; Balar, O.; Niederhausern, A.; Regazzi, A. M.; Ratna, N.; Funt, S. A.; Teo, M. Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • HER2 mutation and bladder cancer (BC): Prevalence and clinical outcomes
    Meeting Abstract

    Shah, N. J.; Aggen, D. H.; Zheng, J.; Niederhausern, A.; Alam, S. M.; Balar, O.; Bahadur, N.; Watson, A.; Regazzi, A. M.; Ratna, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Neoadjuvant nivolumab (N) + ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC): Updated results
    Meeting Abstract

    Sternschuss, M.; Guercio, B. J.; Pietzak, E. J.; Ponomarev, M.; Regazzi, A. M.; Quinlan, C.; Aggen, D. H.; Goh, A. C.; Cha, E. K.; Donat, S. M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save